These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2343070)

  • 1. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.
    Jann MW; Lam YW; Chang WH
    Psychopharmacology (Berl); 1990; 101(1):107-11. PubMed ID: 2343070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio.
    Lam YW; Chang WH; Jann MW; Chen H
    Neuropsychopharmacology; 1992 Aug; 7(1):33-9. PubMed ID: 1524655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients.
    Chang WH; Lin SK; Lane HY; Wei FC; Hu WH; Lam YW; Jann MW
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Jul; 22(5):723-39. PubMed ID: 9723115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interconversion between haloperidol and reduced haloperidol in healthy volunteers.
    Chakraborty BS; Hubbard JW; Hawes EM; McKay G; Cooper JK; Gurnsey T; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1989; 37(1):45-8. PubMed ID: 2591462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
    Chang WH; Lam YW; Jann MW; Chen H
    Psychopharmacology (Berl); 1992; 106(4):517-22. PubMed ID: 1579624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.
    Young D; Midha KK; Fossler MJ; Hawes EM; Hubbard JW; McKay G; Korchinski ED
    Eur J Clin Pharmacol; 1993; 44(5):433-8. PubMed ID: 8359179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination half-life and bioavailability of haloperidol in schizophrenic patients.
    Magliozzi JR; Hollister LE
    J Clin Psychiatry; 1985 Jan; 46(1):20-1. PubMed ID: 3965439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible metabolism of drugs.
    Jann MW; Lam YW; Gray EC; Chang WH
    Drug Metabol Drug Interact; 1994; 11(1):1-24. PubMed ID: 12369591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?
    Chang WH
    Psychopharmacology (Berl); 1992; 106(3):289-96. PubMed ID: 1570373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of haloperidol.
    Froemming JS; Lam YW; Jann MW; Davis CM
    Clin Pharmacokinet; 1989 Dec; 17(6):396-423. PubMed ID: 2689040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of haloperidol: an update.
    Kudo S; Ishizaki T
    Clin Pharmacokinet; 1999 Dec; 37(6):435-56. PubMed ID: 10628896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
    Chang WH; Lin SK; Jann MW
    J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
    Suzuki A; Otani K; Mihara K; Yasui N; Kondo T; Tokinaga N; Furukori H; Kaneko S; Inoue Y; Hayashi K
    Psychopharmacology (Berl); 1998 Feb; 135(4):333-7. PubMed ID: 9539256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
    Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
    Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach to dose reduction in chronic schizophrenia.
    Hirschowitz J; Hitzemann R; Burr G; Schwartz A
    Neuropsychopharmacology; 1991 Sep; 5(2):103-13. PubMed ID: 1834073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
    Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
    Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
    Avent KM; DeVoss JJ; Gillam EM
    Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug holidays and serum haloperidol levels in schizophrenic patients.
    McMillan DE; Fody EP; Couch L; Harrison RH; Newton JE; Reese WG
    J Clin Psychiatry; 1986 Jul; 47(7):373-4. PubMed ID: 3722135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.
    Kalgutkar AS; Taylor TJ; Venkatakrishnan K; Isin EM
    Drug Metab Dispos; 2003 Mar; 31(3):243-9. PubMed ID: 12584149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.